[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249. doi:10.3322/caac.21660.
|
[2] |
Sadate A, Occean BV, Beregi JP, et al. Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. Eur J Cancer, 2020, 134: 107-114. doi:10.1016/j.ejca.2020.04.035.
pmid: 32502939
|
[3] |
孟瑞瑞, 刘圆圆, 官新立, 等. 低剂量螺旋CT肺癌筛查的研究现状与进展. 实用肿瘤学杂志, 2020, 34(4): 372-376. doi:10.11904/j.issn.1002-3070.2020.04.015.
|
[4] |
张温馨, 潘宇, 李峒作, 等. 肺癌筛查的卫生经济学评价研究. 中国卫生经济, 2023, 42(8): 78-81.
|
[5] |
梁迪, 师金, 李道娟, 等. 人群肺癌筛查的研究进展. 中国肿瘤, 2023, 32(1): 46-53. doi:10.11735/j.issn.1004-0242.2023.01.A008.
|
[6] |
Bonney A, Malouf R, Marchal C, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev, 2022, 8(8): CD013829. doi:10.1002/14651858.CD013829.pub2.
|
[7] |
Wood DE, Kazerooni EA, Aberle D, et al. NCCN Guidelines insights: lung cancer screening, version 1.2022. J Natl Compr Canc Netw, 2022, 20(7): 754-764. doi:10.6004/jnccn.2022.0036.
|
[8] |
中国肺癌早诊早知专家组, 中国西部肺癌研究协作中心. 中国肺癌低剂量CT筛查指南(2023年版). 中国肺癌杂志, 2023, 26(1): 1-9. doi:10.3779/j.issn.1009-3419.2023.102.10.
|
[9] |
Jonas DE, Reuland DS, Reddy SM, et al. Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US preventive services task force. JAMA, 2021, 325(10): 971-987. doi:10.1001/jama.2021.0377.
pmid: 33687468
|
[10] |
艾飞玲, 胡葵茹, 石钰霖, 等. 基于纽卡斯尔-渥太华量表对中国吸烟队列研究文献的质量评价. 中华疾病控制杂志, 2021, 25(6): 722-729. doi:10.16462/j.cnki.zhjbkz.2021.06.018.
|
[11] |
Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension. JAMA, 2022, 328(22): 2252-2264. doi:10.1001/jama.2022.21022.
pmid: 36511921
|
[12] |
Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med, 2015, 191(10): 1166-1175. doi:10.1164/rccm.201408-1475OC.DOI:10.1164/rccm.201408-1475OC.
|
[13] |
Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med, 2016, 193(5): 542-551. doi:10.1164/rccm.201505-1040OC.
|
[14] |
Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax, 2017, 72(9): 825-831. doi:10.1136/thoraxjnl-2016-209825.
pmid: 28377492
|
[15] |
Doroudi M, Pinsky PF, Marcus PM. Lung cancer mortality in the lung screening study feasibility trial. JNCI Cancer Spectr, 2018, 2(3): pky042. doi:10.1093/jncics/pky042.
|
[16] |
Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the mild trial: new confirmation of lung cancer screening efficacy. Ann Oncol, 2019, 30(7): 1162-1169. doi:10.1093/annonc/mdz117.
pmid: 31987384
|
[17] |
National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. J Thorac Oncol, 2019, 14(10): 1732-1742. doi:10.1016/j.jtho.2019.05.044.
pmid: 31260833
|
[18] |
Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial. Int J Cancer, 2020, 146(6): 1503-1513. doi:10.1002/ijc.32486.
pmid: 31162856
|
[19] |
de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomi-zed trial. N Engl J Med, 2020, 382(6): 503-513. doi:10.1056/NEJMoa1911793.
|
[20] |
Li N, Tan F, Chen W, et al. One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. Lancet Respir Med, 2022, 10(4): 378-391. doi:10.1016/S2213-2600(21)00560-9.
pmid: 35276087
|
[21] |
Miglioretti DL, Lange J, van den Broek JJ, et al. Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. Ann Intern Med, 2016, 164(4): 205-214. doi:10.7326/M15-1241.
pmid: 26756460
|
[22] |
Dobbin KK, Ebell M. Should we expect all-cause mortality reductions in large screening studies?. Br J Gen Pract, 2018, 68(671): 290-291. doi:10.3399/bjgp18X696545.
|
[23] |
Passiglia F, Cinquini M, Bertolaccini L, et al. Benefits and harms of lung cancer screening by chest computed tomography: a systematic review and meta-analysis. J Clin Oncol, 2021, 39(23): 2574-2585. doi:10.1200/JCO.20.02574.
|
[24] |
Shemesh J, Henschke CI, Shaham D, et al. Ordinal scoring of coronary artery calcifications on low-dose CT scans of the chest is predictive of death from cardiovascular disease. Radio-logy, 2010, 257(2): 541-548. doi:10.1148/radiol.10100383.
|
[25] |
Rossaki FM, Hurst JR, van Gemert F, et al. Strategies for the prevention, diagnosis and treatment of copd in low- and middle-income countries: the importance of primary care. Expert Rev Respir Med, 2021, 15(12): 1563-1577. doi:10.1080/17476348.2021.1985762.
|
[26] |
Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, 2021, 397(10290): 2182-2193. doi:10.1016/S0140-6736(21)00731-5.
pmid: 33991479
|
[27] |
Doubeni CA, Gabler NB, Wheeler CM, et al. Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR consortium. CA Cancer J Clin, 2018, 68(3): 199-216. doi:10.3322/caac.21452.
|
[28] |
Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst, 2000, 92(16): 1308-1316. doi:10.1093/jnci/92.16.1308.
pmid: 10944552
|